


New!

“One small dose for cats, one giant leap for feline vaccination.”



An innovation in feline vaccination



Easier for veterinarians



More cat-friendly

Now in reduced volume*

0.5 mL

Purevax[®]
Always closer to cat needs



*PUREVAX Rabies remains in 1mL

©Boehringer Ingelheim

PUREVAX RC, PUREVAX RCP, PUREVAX RCPCh, PUREVAX FeLV, PUREVAX RCP FeLV, PUREVAX RCPCh FeLV, PUREVAX Rabies contain attenuated feline rhinotracheitis herpesvirus (FHV F2) strain, inactivated feline Caliciviruses antigens (FCV 431 and G1), attenuated feline panleucopenia virus (PLI IV), attenuated Chlamydomphila felis (905 strain), FeLV recombinant canarypox virus (vCP97), Rabies recombinant canarypox virus (vCP65). INDICATIONS FOR USE: Depending on the combination of components used, active immunisation of cats aged 8 weeks (12 weeks for PUREVAX rabies) and older: – against feline viral rhinotracheitis to reduce clinical signs, – against calicivirus infection to reduce clinical signs, – against feline panleucopenia to prevent mortality and clinical signs, – against Chlamydomphila felis infection to reduce clinical signs, – against leukaemia to prevent persistent viraemia and clinical signs of the related disease, – against rabies to prevent mortality. For information about adverse reactions, precautions and warnings for these products, please refer to the products packaging and package leaflet. Further information is available from the data sheet or on request from Boehringer Ingelheim Vetmedica GmbH, Binger Str. 173, 55216 Ingelheim am Rhein, Germany. PUREVAX is a registered trademark of Boehringer Ingelheim Animal Health Ltd. © Boehringer Ingelheim Ltd 2018. All rights reserved.

 **Boehringer
Ingelheim**